Allogene Therapeutics Stock Investor Sentiment
| ALLO Stock | USD 3.47 0.01 0.29% |
About 59% of Allogene Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Allogene Therapeutics suggests that many traders are alarmed. Allogene Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Allogene Therapeutics. The current market sentiment, together with Allogene Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Allogene Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Allogene Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Allogene daily returns and investor perception about the current price of Allogene Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Allogene |
Allogene Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Allogene Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Allogene Therapeutics that are available to investors today. That information is available publicly through Allogene media outlets and privately through word of mouth or via Allogene internal channels. However, regardless of the origin, that massive amount of Allogene data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Allogene Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Allogene Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Allogene Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Allogene Therapeutics alpha.
Allogene Therapeutics Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | We Think Allogene Therapeutics Needs To Drive Business Growth Carefully | 03/01/2024 |
2 | Acquisition by Arie Belldegrun of 4710120 shares of Allogene Therapeutics subject to Rule 16b-3 | 03/07/2024 |
3 | Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update | 03/14/2024 |
4 | ALLO Stock Earnings Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 | 03/15/2024 |
5 | Allogene Therapeutics, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat | 03/18/2024 |
6 | Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3 | 03/27/2024 |
7 | Disposition of 3000 shares by Veer Bhavnagri of Allogene Therapeutics at 6.85 subject to Rule 16b-3 | 03/28/2024 |
8 | Acquisition by Joshua Kazam of 116120 shares of Allogene Therapeutics at 5.7 subject to Rule 16b-3 | 04/02/2024 |
9 | How Allogene Stock Stands Out in a Strong Industry | 04/08/2024 |
10 | Disposition of 10000 shares by Owen Witte of Allogene Therapeutics at 16.5 subject to Rule 16b-3 | 04/11/2024 |
11 | Allogene Therapeutics, Inc. Short Interest Update - Defense World | 04/17/2024 |
Check out Allogene Therapeutics Hype Analysis, Allogene Therapeutics Correlation and Allogene Therapeutics Performance. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.55) | Return On Assets (0.27) | Return On Equity (0.56) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.